


5

CLAIMS

1. A compound of the formula



10

Formula (I)

wherein Ar is selected from the group consisting of aryl, heteroaryl, benzoheteroaryl, pyridone, pyridazinone, and pyrimidone;

15 n is 1-6;

R₁ and R₂ are independently H, alkyl or aralkyl or R₁ and R₂ along with N can form a pyrrolidine, piperadine, piperazine, morpholine, benzopyrrolidine, benzopiperadine or benzopiperazine ring, or R₁ and L₁ or R₁ and one carbon of (CH₂)_n can form a 5, 6, or 7 membered ring;

20 R₃ is H, alkyl or aralkyl;

X and Y are independently C or N;

R₄, R₅, and R₆ are independently selected from the group consisting of H, alkyl, aralkyl, aryl, heteroaryl, benzoheteroaryl, hydroxyl, halo, haloalkyl, alkoxy, aminocarbonyl and aminosulfonyl or R₅ and R₆ together can form a 5-6 membered aromatic ring or a 5-7 membered aliphatic ring;


25 L₁ is selected from the group consisting of a single bond, O, NR₇, CO, SO₂, NR₈CO, NR₉SO₂, NR₁₀CONR₁₁, NR₁₂SO₂NR₁₃, arene, heteroarene, pyridone, pyrimidone and pyridazinone;

L₂ and L₃ are independently selected from the group consisting of a single bond, CH₂, NR₁₄, CO and SO₂; and

30 R₇-R₁₄ are independently selected from the group consisting of H, alkyl, aryl and aralkyl or R₈ and CO and Ar can form pyridone, pyridazinone, and pyrimidone, and the pharmaceutically

5 acceptable salts thereof.

2. A compound of claim 1 of the formula




10

wherein each R_{15} is independently H, alkyl, aralkyl, haloalkyl, aryl, heteroaryl, benzoheteroaryl, alkoxy, aminocarbonyl or aminosulfonyl and two of R_{15} can form a 5-6 membered aromatic ring or a 5-7 membered aliphatic ring; m is 0-3; and

15 R_1 , R_2 , R_4 , R_5 , R_6 , n , X and Y are as defined in claim 1, and the pharmaceutically acceptable salts thereof.

3. A compound of claim 1 of the formula:



20

wherein each R_{15} is independently H, alkyl, aralkyl, haloalkyl, aryl, heteroaryl, benzoheteroaryl, alkoxy, aminocarbonyl or aminosulfonyl and two of R_{15} can form a 5-6 membered aromatic ring or a 5-7 member aliphatic ring;

25 M is 0-3; and

R_1 , R_2 , R_4 , R_5 , R_6 , n and X are as defined in claim 1, and the pharmaceutically acceptable salts thereof.

- 5 4. A compound of claim 1 selected from the group consisting of:
- {4-Chloro-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(4-Benzylpiperidin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {4-Chloro-3-[2-(4-phenylpiperidin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- 10 {3-[2-(4-Benzylpiperazin-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(Benzylmethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(4-Benzylpiperidin-1-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;
- {3-[3-(4-Benzylpiperidin-1-yl)propoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- 15 {3-[2-(1-Methyl-1-phenylethylamino)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- [3-(2-Benzylaminoethoxy)phenyl]-(2-methylquinolin-4-yl)amine;
- 1-(1-{2-[3-(2-Methylquinolin-4-ylamino)phenoxy]ethyl}-4-phenylpiperidin-4-yl)ethanone;
- [3-(3-Benzylaminopropoxy)phenyl]-(2-methylquinolin-4-yl)amine;
- {3-[2-(2-Benzylimidazol-1-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- 20 (1-{2-[3-(2-Methylquinolin-4-ylamino)phenoxy]ethyl}piperidin-4-yl)diphenylmethanol;
- 4-Benzyl-1-{2-[3-(2-tert-butylquinolin-4-ylamino)phenoxy]ethyl}piperidin-4-ol;
- 4-Benzyl-1-{2-[3-(2-methylquinolin-4-ylamino)-5-trifluoromethylphenoxy]ethyl}piperidin-4-ol;
- {3-[2-(4-Benzylpiperidin-1-yl)ethoxy]phenyl}-(2,6-dimethylpyrimidin-4-yl)amine;
- 25 {3-[2-(5-Benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethoxy]phenyl}-(2-methylquinolin-4-yl)amine;
- {3-[2-(4-Benzylpiperazin-1-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;
- (2-Methylquinolin-4-yl)-{3-[2-(4-phenylpiperidin-1-yl)ethoxy]-5-trifluoromethylphenyl}amine;
- 30 {3-[3-(1-Methyl-1-phenylethylamino)propoxy]phenyl}-(2-methylquinolin-4-yl)amine.
- {3-[2-(5-Benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethoxy]-5-trifluoromethylphenyl}-(2-methylquinolin-4-yl)amine;
- N-(2-{1-[2-(3-Fluorophenyl)ethyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl}ethyl)-3-

- 5 (2-methylquinolin-4-ylamino)benzamide;
 N-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;
 N-[2-(1,3-Dihydroisoindol-2-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;
 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2-methyl-5-(2-methylquinolin-4-ylamino)benzamide;
 10 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2-hydroxy-5-(2-methylquinolin-4-ylamino)benzamide;
 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-3-(2-trifluoromethylquinolin-4-ylamino)benzamide;
 15 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2,4,6-trimethyl-3-(2-methylquinolin-4-ylamino)benzamide;
 2-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-4-(2-methylquinolin-4-ylamino)-2,3-dihydroisoindol-1-one;
 3-(2-Methylquinolin-4-ylamino)-N-[2-(1,3,4,5-tetrahydrobenzo[c]azepin-2-yl)ethyl]benzamide;
 20 N-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-2,5-bis(2-methylquinolin-4-ylamino)benzamide;
 3-(2-Methylquinolin-4-ylamino)-N-[2-(octahydro-cis-isoquinolin-2-yl)ethyl]benzamide;
 N-(2-Azepan-1-ylethyl)-3-(2-methylquinolin-4-ylamino)benzamide;
 25 N-(2-Benzylaminoethyl)-3-(2-methylquinolin-4-ylamino)benzamide;
 4-({2-[3-(2-Methylquinolin-4-ylamino)-benzoylamino]ethylamino}methyl)benzoic acid;
 N-[2-(2,2-Dimethylpropylamino)ethyl]-3-(2-methylquinolin-4-ylamino)benzamide;
 N-[2-(4-Benzylpiperazin-1-yl)ethyl]-3-(2-methylquinolin-4-ylamino)benzenesulfonamide;
 {3-[5-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)isoxazol-3-yl]phenyl}-(2-methylquinolin-4-yl)amine;
 30 {3-[3-(3,4-Dihydro-1H-isoquinolin-2-yl)propyl]-4-methylphenyl}-(2-methylquinolin-4-yl)amine;
 N¹-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)ethyl]-N⁷-(2-methylquinolin-4-yl)-1,2,3,4-tetrahydronaphthalene-1,7-diamine;

5 [3'-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-yl]-(2-methylquinolin-4-yl)amine;
 {3-[2-(4-Benzylpiperidin-1-yl)ethanesulfonyl]phenyl}-(2-methylquinolin-4-yl)amine;
 N-[2-(4-Benzylpiperidin-1-yl)ethyl]-N'-(2-methylquinolin-4-yl)pyrimidine-4,6-diamine; and
 3-(4-Benzylpiperidin-1-yl)-1-[3-(2-methylquinolin-4-ylamino)phenyl]propan-1-one oxime;

10 5. A pharmaceutical composition comprising a compound of claim 1 and a
 pharmaceutically acceptable carrier or excipient.

6. A method of treating conditions associated with urotensin-II imbalance by
 antagonizing the urotensin-II receptor which comprises administering to a patient in need
 15 thereof, a compound of claim 1.

7. A method according to claim 6 wherein the condition is selected from the group
 consisting of congestive heart failure, stroke, ischemic heart disease, angina, myocardial
 ischemia, cardiac arrhythmia, essential and pulmonary hypertension, renal disease, acute and
 20 chronic renal failure, end stage renal disease, peripheral vascular disease, male erectile
 dysfunction, diabetic retinopathy, intermittent claudication/ischemic limb disease,
 ischemic/hemorrhagic stroke, COPD, restenosis, asthma, neurogenic inflammation, migraine,
 metabolic vasculopathies, bone/cartilage/joint diseases, arthritis and other inflammatory
 diseases, fibrosis, pulmonary fibrosis, sepsis, atherosclerosis, dyslipidemia, addiction,
 25 schizophrenia, cognitive disorders, Alzheimers disease, impulsivity, anxiety, stress,
 depression, Parkinsons, movement disorders, sleep-wake cycle, inventive motivation, pain,
 neuromuscular function, diabetes, gastric reflux, gastric motility disorders, ulcers and
 genitourinary diseases.